Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Carboxybenzeneacetic Acid SCHEMBL4828304 | 0.84 | BCAT2 (0.59) | FOLH1ALDH1A1ALOX15TSHRHMGB1 | |
| SCHEMBL1756158 | 0.82 | FOLH1 (0.59) | FOLH1ALDH1A1ALOX15TSHRHMGB1 | |
| 2-Carboxybenzeneacetic Acid SCHEMBL1891118 | 0.82 | AKR1B1 (0.61) | FOLH1ALDH1A1ALOX15TSHRHMGB1 | |
| 2-Carboxybenzeneacetic Acid SCHEMBL27477 | 0.82 | AKR1B1 (0.61) | FOLH1ALDH1A1ALOX15TSHRHMGB1 | |
| SCHEMBL69352 | 0.81 | TSHR (0.68) | FOLH1ALDH1A1ALOX15TSHRHMGB1 | |
| SCHEMBL30365583 | 0.81 | FOLH1 (0.76) | FOLH1ALDH1A1ALOX15TSHRHMGB1 | |
| SCHEMBL70392 | 0.81 | FOLH1 (0.76) | FOLH1ALDH1A1ALOX15TSHRHMGB1 | |
| SCHEMBL5609604 | 0.81 | AKR1C3 (0.55) | ALDH1A1TSHRMAPTGAAAKR1C3 | |
| 2-Carboxybenzeneacetic Acid SCHEMBL3975685 | 0.80 | BCAT2 (0.59) | FOLH1ALDH1A1ALOX15TSHRHMGB1 | |
| Water SCHEMBL28844415 | 0.80 | FOLH1 (0.57) | FOLH1ALDH1A1ALOX15TSHRHMGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | claimed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | claimed |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-8791155-B2 | Chroman derivatives | EDISON PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | disclosed |
| US-20120088783-A1 | CHROMAN DERIVATIVES | AMPERE LIFE SCIENCES, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8044097-B2 | Chroman derivatives | AMPERE LIFE SCIENCES, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-7875607-B2 | Neurodegenerative disorders; antiinflammatory agents; antiischemic agents; neuropathic pain; antiepileptic agents; Parkinson's disease; Alzheimer's disease; antidiabetic agents; 3-(6-Hydroxy-2-methyl-3,4,7,8,9,10-hexahydro-7,10-methano-2H -benzo[h]chromen-2-yl)-propionic acid methyl ester | AMPERE LIFE SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090192179-A1 | CHROMAN DERIVATIVES | EDISON PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090170814-A1 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES | EDISON PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7514461-B2 | Lipoxygenase moderators; autoimmune disease; neurodegenerative disease; respiratory system disorders; cardiovascular disorders; Alzheimer's disease; Parkinson's disease; amyotropic lateral sclerosis | EDISON PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-0627659-A1 | Stabilizers for photothermographic materials with nitrile blocking groups | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5358843-A | Deblocking with fluoride ions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-10-25 | — | — | US | disclosed |
| US-5300420-A | Resistant to thermal release during shelf aging | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| US-5298390-A | Heterocyclic sulfides, sulfoxides and sulfones, post-processing stabilization of unreacted silver halide | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-03-29 | — | — | US | disclosed |
| EP-0588717-A2 | Post-processing stabilizers for photothermographic articles | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-03-23 | — | — | EP | disclosed |
| US-5175081-A | Post-processsing stabilization of photothermographic emulsions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-12-29 | — | — | US | disclosed |
| US-5158866-A | POST-PROCESSING STABILIZATION OF PHOTOTHERMOGRAPHIC EMULSIONS WITH AMIDO COMPOUNDS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0480568-A2 | Post-processing stabilization of photothermographic emulsions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-04-15 | — | — | EP | disclosed |
| EP-0473351-A2 | Post-processing stabilization of photothermographic emulsions with amido compounds | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088783-A1 | CHROMAN DERIVATIVES | CYP11B1, CYP11B2, TFAM | FOLH1 4773/4885ALDH1A1 986/4885ALOX15 7/4885 |
| US-20090192179-A1 | CHROMAN DERIVATIVES | CYP11B1, CYP11B2, TFAM | FOLH1 4773/4885ALDH1A1 986/4885ALOX15 7/4885 |
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | FOLH1 3243/4885ALDH1A1 4059/4885ALOX15 240/4885 |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | FOLH1 3222/4885ALDH1A1 792/4885ALOX15 782/4885 |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | FOLH1 3222/4885ALDH1A1 792/4885ALOX15 782/4885 |
| US-20090170814-A1 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES | COQ8A, TFAM, CS | FOLH1 3755/4885ALDH1A1 926/4885ALOX15 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.